Nebilet

Nebilet is a brand name for nebivolol, a beta-1 selective adrenergic blocker with nitric oxide–mediated vasodilation. It is used primarily to treat essential hypertension and is marketed in several countries under the Nebilet brand, among others.

Nebivolol works by blocking beta-1 receptors in the heart, which reduces heart rate, contractility, and the release of renin, contributing to lowered blood pressure. In addition, nebivolol stimulates endothelial nitric oxide production, producing vasodilation that further decreases vascular resistance. This combination gives nebivolol a cardioselective profile at standard doses with a vasodilatory component that can aid blood pressure control.

The primary indication for nebivolol is treatment of essential hypertension in adults. In some regions, regional labeling or clinical practice may include additional cardiovascular uses, but hypertension remains the standard, approved indication. It may be used as monotherapy or in combination with other antihypertensive agents, depending on patient needs.

Nebilet is available as tablets in 5 mg, 10 mg, and 20 mg strengths. The starting dose is commonly 5 mg once daily, with titration based on response to reach about 10–20 mg daily; the typical maximum is 40 mg once daily, adjusted to achieve target blood pressure while monitoring for side effects.

Common adverse effects include dizziness, headache, fatigue, bradycardia, and hypotension. The drug can mask some signs of hypoglycemia and may affect glucose and lipid metabolism. While beta-1 selectivity reduces risk of bronchospasm, caution is warranted in patients with asthma or COPD. Abrupt discontinuation is not advised, as it can cause rebound symptoms. Nebivolol may interact with other antihypertensives and with agents that slow heart rate.